

RECEIVED

FEB 08 2002

TECH CENTER 1600/2900



Form PTO-1449
U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No. 55669-Z/JPW/BJA Serial No. 09/832,648

Applicants

Cy A. Stein

Filing Date April 11, 2001

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate
<i>Ja</i>	US	5	0	2	3	2	4	3	6/11/91	Tullis, R.			
	US	5	1	0	7	0	6	5	4/21/92	Schewmaker, et al.			
	US	5	5	8	7	4	7	0	12/24/96	Cook, et al.			
	US	5	6	7	0	6	3	3	8/23/97	Cook, et al.			
	US	5	7	3	4	0	3	3	3/31/98	Reed, J.			RECEIVED
	US	5	8	4	3	7	1	3	12/1998	Yoshida et al.			FEB 08 2002
	US	5	7	7	6	9	0	5	7/1998	Gibbons et al.			TECH CENTER 1600/2900
	US	5	7	0	2	8	9	7	12/1997	Reed et al.			
	US	5	4	9	6	5	4	7	3/1996	Lam et al.			
	US	5	5	9	3	9	7	4	1/1997	Rosenberg et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>Ja</i>		9 8 0 5 7 7 7	2/1998	WO				
		9 5 1 5 4 0 0	6/1995	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Ja</i>	Agrawal, S., et al., <u>Proc. Natl. Acad. Sci. U.S.A. (1988) Vol. 85:7079-7083;</u>
	Beaucage, S., and Caruthers, M., <u>Tetrahedron Lett. (1981) Vol. 22:1859-1862;</u>
	Cook, P.D., "Medicinal Chemistry of Antisense Oligonucleotides - future opportunities" (1991) <u>Anti Cancer Drug Design</u> Vol.

EXAMINER

DATE CONSIDERED

2-23-04

*EXAMINER: Initial if citation considered whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Cy A. Stein
 U.S. Serial No.: 09/832,648
 Filed: April 11, 2001
 Exhibit A

RECEIVED


FEB 08 2002

Sheet 2 of 3

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

SERIAL NO.
55669-Z/JPW/BJA 09/832,648INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

APPLICANT

Cy A. Stein

FILING DATE
April 11, 2001GROUP ART UNIT
RECEIVED

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

10:585-607;	FEB 08 2002
Ghosh, S., et al., <u>J. Biol. Chem.</u> (1990) Vol. 265:2935-2940;	TECH CENTER 1600/2900
Hemken, P., et al., <u>J. Biol. Chem.</u> (1992) Vol. 267:9948-0057;	
Iverson, P., <u>Anti-Cancer Drug Des.</u> (1991) Vol. 6:531-538;	
Krajewska, M. et al. "Immunohistochemical analysis bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancer." <u>Am. J. Pathol.</u> (1996) Vol. 148:1567-1576;	
Luedke, G.H., Ziegler, Al., Stahel, R.A., and Zangemeister-Wittke, U., "Antisense oligonucleotides targeting sequences shared by the Bcl-2 and the Bcl-xL mRNA efficiently downregulate expression of both proteins and induce apoptosis of lung cancer cells." Division of Oncology, Department of Internal Medicine, University Hospital, CH-8091 Zurich, Switzerland. (Abstract #1140 from 88 Ann. Meet. AACR, April 12-16, 1997, Vol. 38, (March 1997), p. 171);	
Milligan et al., "Current Concepts in Antisense Drug Design," <u>Journal of Medicinal Chemistry</u> (July 9, 1993) Vol. 36:1924-1937;	
Pollman et al., "Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease," <u>Nature Medicine</u> (1998) Vol. 4:222-227 (Exhibit 15);	
Ratajczak, et al., <u>Proc. Natl. Acad. Sci. U.S.A.</u> (1992) Vol. 89:11823;	
Stein, C. et al., <u>Pharmac. Ther.</u> (1991) Vol. 52:365-384;	
Uhlmann, E. And Peyman A., "Antisense Oligonucleotides: A New Therapeutic Principle" <u>Chem. Rev.</u> (1990) Vol. 90:544-579;	

EXAMINER

DATE CONSIDERED

2-28-09

*EXAMINER: Initial if citation considered whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)ATTY. DOCKET NO. SERIAL NO.
55669-Z/JPW/BJA 09/832,648APPLICANT
Cy A. SteinFILING DATE
April 11, 2001 GROUP ART UNIT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Wang, Z. et al., "Induction of bcl-xl by CD40 Engagement Rescues slg-induced Apoptosis in Murine B Cells", The Journal of Immunology

(1995) Vol. 155:3722-3725;

Zhao, Q., et al., Antisense Research and Development (1993) Vol. 3:53-66;

Zon, G., "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," Pharmaceutical Research (November 9, 1988) Vol. 5:539-549;

"Antisense 1997: A roundtable on the state of the industry" (1997) Nature Biotechnology. 15:519-524;

Crooke, S.T., "Vitravene - Another piece of the Mosaic". (1998) Antisense and Nucleic Acid Drug. Dev. 8:vii-viii;

Gewritz et al. "Facilitating oligonucleotide delivery: helping antisense deliver on its promise" (1996) PNAS 93:3161-3163;

Gura, T. "Antisense has growing pains" (1995) Science 270:575-577;

Stein C.A. "Keeping the Biotechnology of antisense in context" (1999) Nature Biotechnology 17:209;

Stull et al. "Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects" (1995) Pharm. Res. 12:465-483;

Rojanasakul, Y. "Antisense oligonucleotide therapeutics: Drug delivery and targeting" (1996) Adv. Drug Delivery Rev. 18:115-131.

EXAMINER

DATE CONSIDERED

2-23-04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FEB 08 2002

TECH CENTER 1600/2900